Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1982 Oct;70(4):823–831. doi: 10.1172/JCI110678

Familial Hypercholesterolemia

EVIDENCE FOR A NEWLY RECOGNIZED MUTATION DETERMINING INCREASED FIBROBLAST RECEPTOR AFFINITY BUT DECREASED CAPACITY FOR LOW DENSITY LIPOPROTEIN IN TWO SIBLINGS

Richard E Ostlund Jr 1,2,3, Richard A Levy 1,2,3, Joseph L Witztum 1,2,3, Gustav Schonfeld 1,2,3
PMCID: PMC370290  PMID: 6288770

Abstract

Cultured skin fibroblasts were obtained from two siblings with classic clinical features of homozygous familial hypercholesterolemia. Plasma cholesterol values were 970 and 802 mg/100 ml in the siblings, 332 mg/100 ml in the mother, and 426 mg/100 ml in the father. Fibroblast receptor-specific capacity for binding and degradation of 125I-low density lipoprotein (LDL) at 37°C was 11% of normal, consistent with the diagnosis of “homozygous LDL receptor-defective” hypercholesterolemia, a disorder in which LDL binding activity is low but detectable.

The residual LDL receptor activity was clearly qualitatively abnormal. The Michaelis constant (Km) for 125I-LDL was reduced to 20-40% of normal, indicating a substantially increased affinity for LDL. Increased affinity and reduced capacity for 125I-LDL are also found when normal fibroblasts are assayed at 4°C. As the temperature is raised to 37°C surface LDL binding affinity decreases while capacity increases. At 4°C the fibroblasts of our subjects had an affinity for LDL indistinguishable from normal cells assayed at that temperature and a binding capacity 23% of normal. However, only small changes in affinity and capacity occurred upon increasing the temperature to 37°C. When 125I-apoprotein E-phospholipid vesicles were bound at 37°C the receptor deficiency appeared only half as severe as when 125I-LDL was used as ligand.

A family study suggests that the siblings are genetic compounds rather than homozygotes, having inherited a mutant maternal gene causing absent or silent LDL receptors and a mutant paternal gene resulting in qualitatively altered LDL receptors. It is not clear whether these defects are present at the same or different genetic loci. The altered receptors are characterized by increased affinity and moderately reduced capacity for LDL at 37°C and are accompanied by hypercholesterolemia at least as severe as that associated with familial hypercholesterolemia with absent or nonfunctional LDL receptors.

Full text

PDF
823

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bilheimer D. W., Ho Y. K., Brown M. S., Anderson R. G., Goldstein J. L. Genetics of the low density lipoprotein receptor. Diminished receptor activity in lymphocytes from heterozygotes with familial hypercholesterolemia. J Clin Invest. 1978 Mar;61(3):678–696. doi: 10.1172/JCI108980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Breslow J. L., Spaulding D. R., Lux S. E., Levy R. I., Lees R. S. Homozygous familial hypercholesterolemia. A possible biochemical explanation of clinical heterogeneity. N Engl J Med. 1975 Oct 30;293(18):900–903. doi: 10.1056/NEJM197510302931804. [DOI] [PubMed] [Google Scholar]
  3. Goldstein J. L., Brown M. S. Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. J Biol Chem. 1974 Aug 25;249(16):5153–5162. [PubMed] [Google Scholar]
  4. Goldstein J. L., Brown M. S., Stone N. J. Genetics of the LDL receptor: evidence that the mutations affecting binding and internalization are allelic. Cell. 1977 Nov;12(3):629–641. doi: 10.1016/0092-8674(77)90263-x. [DOI] [PubMed] [Google Scholar]
  5. Goldstein J. L., Brown M. S. The LDL receptor locus and the genetics of familial hypercholesterolemia. Annu Rev Genet. 1979;13:259–289. doi: 10.1146/annurev.ge.13.120179.001355. [DOI] [PubMed] [Google Scholar]
  6. Goldstein J. L., Dana S. E., Brunschede G. Y., Brown M. S. Genetic heterogeneity in familial hypercholesterolemia: evidence for two different mutations affecting functions of low-density lipoprotein receptor. Proc Natl Acad Sci U S A. 1975 Mar;72(3):1092–1096. doi: 10.1073/pnas.72.3.1092. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. HOFSTEE B. H. Non-inverted versus inverted plots in enzyme kinetics. Nature. 1959 Oct 24;184:1296–1298. doi: 10.1038/1841296b0. [DOI] [PubMed] [Google Scholar]
  8. Innerarity T. L., Mahley R. W. Enhanced binding by cultured human fibroblasts of apo-E-containing lipoproteins as compared with low density lipoproteins. Biochemistry. 1978 Apr 18;17(8):1440–1447. doi: 10.1021/bi00601a013. [DOI] [PubMed] [Google Scholar]
  9. Innerarity T. L., Pitas R. E., Mahley R. W. Binding of arginine-rich (E) apoprotein after recombination with phospholipid vesicles to the low density lipoprotein receptors of fibroblasts. J Biol Chem. 1979 May 25;254(10):4186–4190. [PubMed] [Google Scholar]
  10. Mahley R. W., Innerarity T. L., Pitas R. E., Weisgraber K. H., Brown J. H., Gross E. Inhibition of lipoprotein binding to cell surface receptors of fibroblasts following selective modification of arginyl residues in arginine-rich and B apoproteins. J Biol Chem. 1977 Oct 25;252(20):7279–7287. [PubMed] [Google Scholar]
  11. Ostlund R. E., Jr, Hajek S. V., Levy R. A., Witztum J. L. Analysis of lipids and endothelial and smooth muscle cells of umbilical cord in familial homozygous hypercholesterolemia. Metabolism. 1981 Mar;30(3):285–289. doi: 10.1016/0026-0495(81)90153-0. [DOI] [PubMed] [Google Scholar]
  12. Ostlund R. E., Jr, Pfleger B., Schonfeld G. Role of microtubules in low density lipoprotein processing by cultured cells. J Clin Invest. 1979 Jan;63(1):75–84. doi: 10.1172/JCI109281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Patsch W., Witztum J. L., Ostlund R., Schonfeld G. Structure, immunology, and cell reactivity of low density lipoprotein from umbilical vein of a newborn type II homozygote. J Clin Invest. 1980 Jul;66(1):123–129. doi: 10.1172/JCI109825. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Pitas R. E., Innerarity T. L., Arnold K. S., Mahley R. W. Rate and equilibrium constants for binding of apo-E HDLc (a cholesterol-induced lipoprotein) and low density lipoproteins to human fibroblasts: evidence for multiple receptor binding of apo-E HDLc. Proc Natl Acad Sci U S A. 1979 May;76(5):2311–2315. doi: 10.1073/pnas.76.5.2311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Pitas R. E., Innerarity T. L., Mahley R. W. Cell surface receptor binding of phospholipid . protein complexes containing different ratios of receptor-active and -inactive E apoprotein. J Biol Chem. 1980 Jun 10;255(11):5454–5460. [PubMed] [Google Scholar]
  16. Schwarz K. B., Witztum J., Schonfeld G., Grundy S. M., Connor W. E. Elevated cholesterol and bile acid synthesis in a young patient with homozygous familial hypercholesterolemia. J Clin Invest. 1979 Sep;64(3):756–760. doi: 10.1172/JCI109520. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Stephens R. E. High-resolution preparative SDS-polyacrylamide gel electrophoresis: fluorescent visualization and electrophoretic elution-concentration of protein bands. Anal Biochem. 1975 May 12;65(1-2):369–379. doi: 10.1016/0003-2697(75)90521-7. [DOI] [PubMed] [Google Scholar]
  18. Weisgraber K. H., Mahley R. W. Apoprotein (E--A-II) complex of human plasma lipoproteins. I. Characterization of this mixed disulfide and its identification in a high density lipoprotein subfraction. J Biol Chem. 1978 Sep 10;253(17):6281–6288. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES